Cannabinoid therapy in chronic pain management

Breanna Joy Privratsky
University of North Dakota

Follow this and additional works at: https://commons.und.edu/pas-grad-posters

Part of the Pharmaceutical Preparations Commons

Recommended Citation
Cannabis Therapy in Chronic Pain Management
Breanna J Privratsky, PA-S
Department of Physician Assistant Studies, University of North Dakota School of Medicine & Health Sciences
Grand Forks, ND 58202-9037

Abstract

- In 1996, the state of California was the first in the union to allow for the use of medical marijuana. Since then, 28 more states have enacted similar laws (National Conference of State Legislatures, [NCSL], 2017).
- As of 2014, the CDC reported opioid deaths were up 369%, which is more than 91 deaths per day from overdose (Centers for Disease Control, [CDC], 2017).

Introduction

- Cannabis, cannabinoids and medical marijuana all encompass a topic which is highly controversial, as well as being scientifically researched in comparison to addictive substances. The Food and Drug Administration (FDA) has approved three different cannabinoid-based products that are currently being used for various medical issues, such as Dronabinol (Marinol®) and Nabilone (Syndros®).
- Limited amounts of research have been conducted due to the Drug Enforcement Administration (DEA) schedule of cannabis as a Schedule 1 drug.
- Chronic pain is a highly discussed topic due to the difficult nature of finding a cure and improving quality of life. Patients who deal with chronic pain are often left with prescription opiates for pain management, all of which have adverse effects.
- Cannabis can be a safer alternative to other drugs and has been linked to a decreased risk of addiction, lessened side effects and a possible decrease in other medication use compared to opiates.

Statement of the Problem

- According to Boucheka, Litinas, and Clauw (2016), opiates are one of the most commonly used medications to treat chronic pain. With that notion, opioid use is also ineffective for many types of pain as well as associated with tolerance and significant morbidity and mortality rates.
- With the ever-growing opioid epidemic, an alternative treatment modality with less risk of what benefit. Cannabinoid therapy could be a potential secondary option rather than continued opiate therapy if research supports the safety and efficacy.

Research Questions

- Is medical cannabis safe to use for chronic pain? What are the documented adverse effects associated with using this medication?
- How addictive is medical cannabis compared to other addictive substances? What addictive qualities are associated with starting this medication?
- What has been shown to be more effective in the treatment of chronic pain, medical cannabis or opiates?

Literature Review

- Cannabinoids for Chronic Pain- Safety and Adverse Events
- Whiting et al. (2015) found in eight of the 28 studies, patients who reported at least 30% decrease in pain were those who used cannabinoids rather than those who used a placebo (OR = 1.41; 95% CI = 0.99-2.00). They also found common adverse events that included dizziness, dry mouth, nausea, fatigue, hallucinations, drowsiness and confusion.
- Results found by Ware, Wang, Shapiro, and Collet (2015), showed medical cannabis users were at increased risk of nonserious adverse events, 8.18, ranging from mild to moderate events such as: headache, nasopharyngitis, nausea, somnolence, and dizziness compared to the 581 events documented in the control (IRR = 1.64; 95% CI = 1.35-1.99). Overall, individuals in the medical cannabis group experienced better pain control than the control (change = 92; 95% CI = 62-123) vs. change = 18; 95% CI = –13).
- Nagert et al. (2017) found no detection of significant differences between the cannabis group compared to the control group when it came to serious adverse events (IRR = 1.08; 95% CI = 0.57-2.04). This study did find long-term effects associated with cannabis use and found it to be associated with cannabinoid hyperemesis syndrome as well as incident cannabis use disorder (OR = 9.5; 95% CI = 6.4-14.1).

Comparison of Adverse Substances to Cannabis

- Feingold, Gooey-Aryeh, Bell, Delayahy, and Lev-Ran (2017) state long-term treatment with opioids may be complicated due to tolerance and addiction, which may not be adequately managed and potentially worsen pain.

In an effort to evaluate the adverse reactions, addictive effects, as well as analgesic and statistical significance will be examined in those who choose to use cannabis products for chronic pain therapy.

Literature Review Cont.

- Cannabinoids for chronic pain management: A systematic review of all relevant literature
- Whiting et al. (2015) found cannabis use for increased health-related quality of life (HRQoL) had vague results and most effects were non-significant or nearing zero. Some reports showed a mild benefit in some pain conditions while in others there was a decrease in HRQOL.
- Narang, Gibson, Wasan, Ross, Michna, Nedeltchev, and Jamison (2003) conducted two phases and found Dronabinol in Phase I had significant pain relief after 8 hours per the total pain relief at 8 hours score (TOTPAR), (20 mg vs placebo at p < .01, 10 mg vs placebo at p < .05). For adjuvant therapy in Phase II, dronabinol proved to have a significant effect in lowering pain from baseline (p < .001), decreasing pain bothersomeness, as well as increased satisfaction in their therapy (p < .01).
- Boucheka, Litinas, and Clauw (2016) evaluated the efficacy of medical cannabis compared to opiates in chronic pain patients. Figure II highlights the changes before and after cannabis use.

Discussion

- The National Institutes of Health (NIH) has supported around 281 projects totaling over $111 million on cannabis research, 49 projects ($82 million) examined therapeutic properties of cannabinoids, and 15 projects ($9 million) focused on (CBD)
- Medical cannabis has multiple adverse events similar to other drugs.
- Medical cannabis has been found to be less addictive and problematic than opiates according to the literature review, reference the pie chart
- Medical cannabis has been shown to improve overall HRQoL and reduce medication need, not always statistically but clinically.
- More research is needed to understand the long-term effects as well as short term outcomes in larger populations.

Applicability to Clinical Practice

- It is difficult to find effective treatments for chronic pain, but having multiple therapy modalities increases the likelihood of controlling pain.
- Alternative therapies will aid in alleviating the current opiate epidemic.
- Medical cannabis has also been shown to be effective for other diseases such as fibromyalgia, neuropathy, multiple sclerosis, cystic fibrosis, migraines and gastrointestinal conditions.
- Medical cannabis is associated with reduced risk of addiction, lessened side effects and a possible decrease in other medication use compared to opiates.

Acknowledgements

To my husband Nick and son Ellis, thank you for supporting and encouraging me so I could achieve my dream.
I wish to express my most sincere appreciation to Julie Solberg, PA-C and Daryl Sieg, PA-C for their support through this program.
A special thank you to Dawn Hackman, MS, AHP, Marilyn G. Klug, PhD, and Andreas Makarakis, MD for their assistance and expertise.

References


To my husband Nick and son Ellis, thank you for supporting and encouraging me so I could achieve my dream.
I wish to express my most sincere appreciation to Julie Solberg, PA-C and Daryl Sieg, PA-C for their support through this program.
A special thank you to Dawn Hackman, MS, AHP, Marilyn G. Klug, PhD, and Andreas Makarakis, MD for their assistance and expertise.